Risk of pocket hematoma in patients on chronic anticoagulation with warfarin undergoing electrophysiological device implantation: A comparison of different peri-operative management strategies

European Review for Medical and Pharmacological Sciences

Volumn 19, Issue 8, 2015, Pages 1461-1479

  Proietti, R ^a,b   Porto, I ^c   Levi, M ^b   Leo, A ^c   Russo, V ^d   Kalfon, E ^b,e   Biondi Zoccai, G ^f   Roux, J F ^b,g   Birnie, D H ^h   Essebag, V ^b,i  

^a UNIVERSITY OF MILAN   (Italy)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c CATHOLIC UNIVERSITY   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e WESTERN GALILEE HOSPITAL   (Israel)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^h UNIVERSITY OF OTTAWA   (Canada)

ⁱ HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

Coagulation; Device; Electrophysiological; Hematoma; Heparin; Pacemaker; Pocket; Warfarin

Indexed keywords

HEPARIN; WARFARIN; ANTICOAGULANT AGENT;

ANTICOAGULATION; ARTICLE; ARTIFICIAL HEART PACEMAKER; HEMATOMA; HIGH RISK PATIENT; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INTERMETHOD COMPARISON; LENGTH OF STAY; META ANALYSIS; PERIOPERATIVE PERIOD; POCKET HEMATOMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW; THROMBOEMBOLISM; ADVERSE EFFECTS; CHEMICALLY INDUCED; COMPARATIVE STUDY; DRUG ADMINISTRATION; OBSERVATIONAL STUDY; PREOPERATIVE CARE; PROCEDURES; RISK FACTOR; TRENDS;

ANTICOAGULANTS; DEFIBRILLATORS, IMPLANTABLE; DRUG ADMINISTRATION SCHEDULE; HEMATOMA; HEPARIN; HUMANS; LENGTH OF STAY; OBSERVATIONAL STUDIES AS TOPIC; PACEMAKER, ARTIFICIAL; PREOPERATIVE CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; WARFARIN;

EID: 84942284108     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. WIEGAND UK, LEJEUNE D, BOGUSCHEWSKI F, BONNEMEIER H, EBERHARDT F, SCHUNKERT H, BODE F. Pocket hematoma after pacemaker or implantable cardioverter defibrillator surgery: influence of patient morbidity, operation strategy, and perioperative antiplatelet/anticoagulation therapy. Chest 2004; 126: 1177-1186.
2. GIUDICI MC, PAUL DL, BONTU P, BAROLD SS. Pacemaker and implantable cardioverter defibrillator implantation without reversal of warfarin therapy. Pacing Clin Electrophysiol 2004; 27: 358-360.
3. TORN M, ROSENDAAL FR. Oral anticoagulation in surgical procedures: risks and recommendations. Br J Haematol 2003; 123: 676-682.
4. KEARON C, HIRSH J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997; 336: 1506-1511.
5. VANLEEUWEN Y, ROSENDAAL FR, CANNEGIETER SC. Prediction of hemorrhagic and thrombotic events in patients with mechanical heart valve prostheses treated with oral anticoagulants. J Thromb Haemost 2008; 6: 451-456.
6. DOUKETIS JD, SPYROPOULOS AC, SPENCER FA, ET AL. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141(Suppl): e326Se350S.
7. Erratum, Chest 2012; 141: 1129.
8. KEARON C, HIRSH J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997; 336: 1506-1515
9. CASTBERG T. Complications from the pacemaker pocket. Prophylaxis, treatment and results. Acta Med Scand Suppl 1976; 596: 51-54.
10. ROMEYER-BOUCHARD C, DA COSTA A, DAUPHINOT V, MESSIER M, BISCH L, SAMUEL B, LAFOND P, RICCI P, ISAAZ K. Prevalence and risk factors related to infections of cardiac resynchronization therapy devices. Eur Heart J 2010; 31: 203-210.
11. BIRNIE DH, HEALEY JS, WELLS GA, VERMA A, TANG AS, KRAHN AD, SIMPSON CS, AYALA-PAREDES F, COUTU B, LEIRIA TL, ESSEBAG V; BRUISE CONTROL Investigators. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med 2013; 368: 2084-2089.
12. LIBERATI A, ALTMAN DG, TETZLAFF J, MULROW C, GØTZSCHE PC, IOANNIDIS JP, CLARKE M, DEVEREAUX PJ, KLEIJNEN J, MOHER D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009; 62: e1-e34.
13. HIGGINS JPT, GREEN S, EDITORS. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008. Available at: http://www.cochrane-handbook.org/
14. WELLS GA, SHEA B, O'CONNELL D, J PETERSON J, WELCH W, LOSOS, TUGWELL P. The New Castle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical-epidemiology/oxford.htm
15. WHITEHEAD A, WHITEHEAD J. A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 1991; 10: 1665-1677.
16. HIGGINS JP, THOMPSON SG, DEEKS JJ, ALTMAN DG. Measuring inconsistency in meta-analyses. B Med J 2003; 327: 557-560.
17. EGGER M, DAVEY SMITH G, SCHNEIDER M, MINDER C. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315: 629-634.
18. MARQUIE C, DE GEETER G, KLUG D, ET AL. Post-operative use of heparin increases morbidity of pacemaker implantation. Europace 2006; 8: 283-287.
19. AMARA W, BEN YOUSSEF I, KAMEL J, GHRISSI I, FARON M, KHOUADJA A, SERGENT J. Hemorrhagic risk of different perioperative anticoagulation protocols in patients implanted with a cardiac pacemaker or defibrillator: retrospective analysis in patients implanted in a community hospital. Ann Cardiol Angeiol (Paris) 2009; 58: 265-271.
20. CHENG M, HUA W, CHEN K, PU J, REN X, ZHAO X, LIU Z, WANG F, CHEN X, ZHANG S. Perioperative anticoagulation for patients with mechanic hear t valve(s) undertaking pacemaker implantation. Europace 2009; 11: 1183-1187.
21. MICHAUD GF, PELOSI F JR, NOBLE MD, KNIGHT BP, MORADY F, STRICKBERGER SA. A randomized trial comparing heparin initiation 6 h or 24 h after pacemaker or defibrillator implantation. J Am Coll Cardiol 2000; 35: 1915-1918.
22. ROBINSON M, HEALEY JS, EIKELBOOM J, SCHULMAN S, MORILLO CA, NAIR GM, BARANCHUK A, RIBAS S, EVANS G, CONNOLLY SJ, TURPIE AG. Postoperative low-molecular- weight heparin bridging is associated with an increase in wound hematoma following surgery for pacemakers and implantable defibrillators. Pacing Clin Electrophysiol 2009; 32: 378-382.
23. GOLDSTEIN DJ, LOSQUADRO W, SPOTNITZ HM. Outpatient pacemaker procedures in orally anticoagulated patients. Pacing Clin Electrophysiol 1998; 21: 1730-1734.
24. THAL S, MOUKABARY T, BOYELLA R, SHANMUGASUNDARAM M, PIERCE MK, THAI H, GOLDMAN S. The relationship between Warfarin, Aspirin, and Clopidogrel continuation in the peri-procedural period and the occurence of hematoma formation after device implantation. Pacing Clin Electrophysiol 2010; 33: 385-388.
25. TOLOSANA JM, BERNE P, MONT L, HERAS M, BERRUEZO A, MONTEAGUDO J, TAMBORERO D, BENITO B, BRUGADA J. Preparation for pacemaker or implantable cardiac defibrillator implants in patients with high risk of thrombo-embolic events: oral anticoagulation or bridging with intravenous heparin? A prospective randomized trial. Eur Heart J 2009; 30: 1880-1884.
26. MILIC DJ, PERISIC ZD, ZIVIC SS, STANOJKOVIC ZA, STOJKOVIC AM, KARANOVIC ND, KRSTIC NH, SALINGER SS. Prevention of pocket related complications with fibrin sealant in patients undergoing pacemaker implantation who are receiving anticoagulant treatment. Europace 2005; 7: 374-379.
27. GHANBARI H, FELDMAN D, SCHMIDT M, OTTINO J, MACHADO C, AKOUM N, WALL TS, DACCARETT M. Cardiac resynchronization therapy device implantation in patients with therapeutic international normalized ratios. Pacing Clin Electrophysiol 2010; 33: 400-406.
28. AHMED I, GERTNER E, NELSON WB, HOUSE CM, DAHIYA R, ANDERSON CP, BENDITT DG, ZHU DW. Continuing warfarin therapy is superior to interrupting warfarin with or without bridging anticoagulation therapy in patients undergoing pacemaker and defibrillator implantation. Heart Rhythm 2010; 7: 745-749.
29. TISCHENKO A, GULA LJ, YEE R, KLEIN GJ, SKANES AC, KRAHN AD. Implantation of cardiac rhythm devices without interruption of oral anticoagulation compared with perioperative bridging with low-molecular weight heparin. Am Heart J 2009; 158: 252-256.
30. TOMPKINS C, CHENG A, DALAL D, BRINKER JA, LENG CT, MARINE JE, NAZARIAN S, SPRAGG DD, SINHA S, HALPERIN H, TOMASELLI GF, BERGER RD, CALKINS H, HENRIKSON CA. Dual antiplatelet therapy and heparin "bridging" significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation. J Am Coll Cardiol 2010; 55: 2376-2382.
31. The Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA). Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J 2009; 30: 2769-2812.
32. KEARON C, HIRSH J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997; 336: 1506-1511.
33. HAMMERSTINGL C, TRIPP C, SCHMIDT H, VON DER RECKE G, OMRAN H. Periprocedural bridging therapy with low-molecular-weight heparin in chronically anticoagulated patients with prosthetic mechanical heart valves: experience in 116 patients from the prospective BRAVE registry. J Heart Valve Dis 2007; 16: 285-292.
34. AL-KHADRA AS. Implantation of pacemakers and implantable cardioverter defibrillators in orally anticoagulated patients. Pacing Clin Electrophysiol 2003; 26: 511-514.
35. PROIETTI R, BIRNIE DH, HEALEY JS, VERMA A, ESSEBAG V. Continued oral anticoagulation during cardiac pacing: the BRUISE CONTROL study. G Ital Cardiol 2013; 1: 724-725.
36. WANG H, XUE Y. A portable, economic drainage device to prevent pocket hematoma of pacemakers. Journal of Medical Colleges of PLA 2009; 24: 167-175.